npj Vaccines (Feb 2024)

A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression

  • Huajun Zhao,
  • Xianyu Shao,
  • Yating Yu,
  • Lulu Huang,
  • Narh Philip Amor,
  • Kun Guo,
  • Changzhen Weng,
  • Weijun Zhao,
  • Ailu Yang,
  • Jiesen Hu,
  • Hongbao Yang,
  • Zhenguang Liu,
  • Qiuju Han,
  • Leilei Shi,
  • Shiyu Sun,
  • Jian Zhang,
  • Ang Lin,
  • Yong Yang

DOI
https://doi.org/10.1038/s41541-024-00813-3
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Here we report on the development and comprehensive evaluations of an mRNA vaccine for chronic hepatitis B (CHB) treatment. In two different HBV carrier mouse models generated by viral vector-mediated HBV transfection (pAAV-HBV1.2 and rAAV8-HBV1.3), this vaccine demonstrates sufficient and persistent virological suppression, and robust immunogenicity in terms of induction of strong innate immune activation, high-level virus-specific antibodies, memory B cells and T cells. mRNA platform therefore holds prospects for therapeutic vaccine development to combat CHB.